UNSPSC 51334002: Spiramide

This classification denotes an antipsychotic agent with the molecular formula C22H26FN3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 471LF4O004, chemically known as 1,3,8-triazaspiro(4.5)decan-4-one, 8-(3-(4-fluorophenoxy)propyl)-1-phenyl- but generally known as spiramide, which bears US NIH Compound Identifier 68186. European Medicines Agency schedules Spiramide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10619MIG.

UNSPSC 51334002 Spiramide is a Commodity code that in recent state and local activity covers the procurement of pharmaceutical products, including naloxone, generic multi-source pharmaceuticals, and over-the-counter products supplied through established distribution channels and wholesaler networks. State and local buyers under this code include county health departments, state health and human services agencies, and cooperative purchasing alliances representing multiple jurisdictions. Seminole County, Florida procures naloxone and drug deactivation systems for community health initiatives; the Texas Health and Human Services Commission has issued a Request for Information to explore direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, solicits manufacturers of generic pharmaceuticals and OTC products for distribution across participating state and local government facilities in Minnesota and Oregon. Recent work involves fixed-price supply contracts with quarterly or ongoing deliveries, compliance with FDA manufacturing standards and Drug Supply Chain Security Act requirements, and pricing flexibility through various net-price and WAC-minus structures.

Activity appears concentrated in the upper Midwest and Southeast. Seminole County, Florida released IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a July 26, 2023 response deadline and a two-year initial term plus one-year renewal option. The Minnesota Multistate Cooperative Purchasing Alliance issued RFP S1070000015802 on January 20, 2026, with a March 26, 2026 deadline for generic multi-source pharmaceuticals and OTC products, requiring vendors to maintain relationships with authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co.) and certify compliance with current Good Manufacturing Practices and Drug Supply Chain Security Act standards. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capability information on direct-to-manufacturer prescription programs, representing preliminary market research ahead of a formal Request for Proposal.